Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 6

1.

28th Annual JPMorgan Healthcare Conference--Exelixis and Nektar Therapeutics.

Gale S, Croasdell G.

IDrugs. 2010 Mar;13(3):139-41.

PMID:
20191424
2.

Evaluation of WO2012037204 and WO2012037226: Exelixis' selective PI3Kδ inhibitors; the basis of a US$251 million deal.

Norman P.

Expert Opin Ther Pat. 2012 Aug;22(8):971-6. doi: 10.1517/13543776.2012.701282. Epub 2012 Jul 6.

PMID:
22768915
3.

Accessing the Exelixis collection.

Artavanis-Tsakonas S.

Nat Genet. 2004 Mar;36(3):207. No abstract available.

PMID:
14981522
4.

Deal watch: Bristol-Myers Squibb and Exelixis collaborate on kinase inhibitors.

[No authors listed]

Nat Rev Drug Discov. 2009 Feb;8(2):98. doi: 10.1038/nrd2822. No abstract available.

PMID:
19180098
5.

Exelixis: integrated drug-discovery and development platform for human therapeutics.

McCarthy AA.

Chem Biol. 2005 Apr;12(4):407-8. No abstract available.

6.

BMS and Exelixis target tumor suppression pathways.

[No authors listed]

Expert Rev Anticancer Ther. 2001 Aug;1(2):167. No abstract available.

PMID:
12113021

Supplemental Content

Support Center